CooperSurgical Adds to Its IVF Business

CooperSurgical Adds to Its IVF Business

by | Apr 12, 2018 4:50 pm | Medical Devices | 0 comments

CooperSurgical (NYSE: COO), a subsidiary of The Cooper Companies, Inc., has added another medical device maker focused on women’s health. This is CooperSurgical’s first acquisition in 2018, and it didn’t go far from its Trumbull, Connecticut offices to find The LifeGlobal Group in Guilford, Connecticut. LifeGlobal is a leading provider of in vitro fertilization (IVF) products and devices, with operating facilities in the United States, Canada, Europe, Hong Kong and distributors in some 90 countries worldwide. The acquisition is expected to strengthen CooperSurgical’s fertility media offering and thus improve its industry leading fertility business overall. The deal... Read More »
CVS, Aetna Lead a Potential Big-Deal Parade

CVS, Aetna Lead a Potential Big-Deal Parade

by | Dec 4, 2017 12:23 am | Managed Care, Pharmaceuticals, Physician Medical Groups, Private Equity | 1 comment

The fourth quarter, and the month of December in particular, are usually busy times for mergers and acquisitions, and often when big deals are announced. With one month to go in Q4:17, the pace may be picking up. Deal volume through December 1 stood at 231 transactions (-39% to last year’s 379), and $19.6 billion (-49% vs. $38.6 billion in Q4:16). But late on December 3, CVS Health (NYSE: CVS) and managed care giant Aetna (NYSE: AET) announced their $69 billion merger. More mega-deals are in the offing. Possibly. The CVS/Aetna deal was first reported in October by The Wall Street Journal, with talk of $200 to $205 per share for Aetna. The final price is $207 per share in cash and... Read More »
Deal(s) of the Week: Teva, Take Two

Deal(s) of the Week: Teva, Take Two

by | Sep 21, 2017 7:14 pm | Pharmaceuticals, Private Equity | 0 comments

Debt has been a key deal driver this year, particularly in the hospital sector, where Community Health Systems (NYSE: CYH), Quorum Health Corporation (NYSE: QHC) and Tenet Healthcare (NYSE: THC) are shedding less desirable assets. Joining them now is generic drug maker Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), which is shouldering $35 billion of debt brought on by its $40.5 billion acquisition of Allergan’s (NYSE: AGN) line of generics, announced in July 2015. The company hasn’t announced an acquisition since September 2016. What a difference a year makes, as generic drug prices have been squeezed and the company has been selling off non-core assets to pay down its... Read More »
Teva Begins to Pare Its Portfolio

Teva Begins to Pare Its Portfolio

by | Sep 14, 2017 8:09 pm | Pharmaceuticals | 0 comments

Last week, Teva Pharmaceutical Industries Ltd. (NYSE: TVA) divested more than $1.1 billion of assets in response to increasing financial pressure. Just this August, Credit Suisse lowered its rating on Teva’s stock from neutral to underperform, citing industry-wide pricing pressure for generic drugs. Credit Suisse’s announcement follows Teva’s acquisition of Allergan’s (NYSE: AGN) generic division, Anda Inc., just a year ago, for $500 million. Teva is looking to pay down more than $35 billion in debt–an amount that exceeds its market value. To do so, the Israeli drug maker has pursued divestiture opportunities for its global Women’s Health business, as well as its Oncology and... Read More »